The company said total product sales for the 3 months ended June 30, 2024 increased 20% (21% for the 6 months), with volume growth of 26% in both periods partially offset by a decline in net selling price of 3% (2% for the 6 months).

1. 01

   The company said total product sales for the 3 months ended June 30, 2024 increased 20% (21% for the 6 months), with volume growth of 26% in both periods partially offset by a decline in net selling price of 3% (2% for the 6 months).

2. 02

   The company said Horizon product sales contributed $1.1 billion over the 3 months, or $2.0 billion over the 6 months, while volume from its other brands grew 10% and 9% over the 3-month and 6-month periods, respectively.

3. 03

   Amgen said operating cash flow for the 6 months of 2024 declined from a year earlier, citing IRS payments timing, including the $1.5 billion repatriation tax payment in Q2 and the $800 million advance deposit in Q1.

4. 04

   Amgen said it paid dividends of $2.4 billion and repaid debt of $1.4 billion in the 6 months of 2024, and used $410 million to retire $544 million of debt principal. The company said it did not repurchase any shares in the same period and that $7.0 billion remained under its authorization.

Key figures

Quarter ended June 30, 2024

Revenue

$8.4B

Operating income

$1.9B

Net income

$746M

EPS

$1.38

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.